Antifungal therapy: Drug-drug interactions at your fingertips

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 2, 2016, Pages 285-289

  Lempers, Vincent J ^a,b   Brüggemann, Roger J ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ARTICLE; DRUG DRUG INTERACTION; DRUG INTERACTION; HEALTH CARE PERSONNEL; HUMAN; FACTUAL DATABASE; PATIENT SAFETY;

ANTIFUNGAL AGENTS; DATABASES, FACTUAL; DRUG INTERACTIONS; HUMANS; PATIENT SAFETY;

EID: 84959861910     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv350     Document Type: Article

References (17)

1. Bruggemann RJ, Alffenaar JW, Blijlevens NM et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009; 48: 1441-58.
2. Nivoix Y, Leveque D, Herbrecht R et al. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008; 47: 779-92.
3. Muilwijk EW, Lempers VJ, Burger DM et al. Impact of special patient populations on the pharmacokinetics of echinocandins. Expert Rev Anti Infect Ther 2015; 13: 799-815.
4. Khoo SH, Bond J, Denning DW. Administering amphotericin B-a practical approach. J Antimicrob Chemother 1994; 33: 203-13.
5. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46: 171-9.
6. Law V, Knox C, Djoumbou Y et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014; 42: D1091-7.
7. Krakower D, Kwan CK, Yassa DS et al. iAIDS: HIV-related internet resources for the practicing clinician. Clin Infect Dis 2010; 51: 813-22.
8. University of Liverpool. HIV Drug Interactions Database. http://www.hiv-druginteractions.org.
9. Sheehan NL, Kelly DV, Tseng AL et al. Evaluation of HIV drug interaction web sites. Ann Pharmacother 2003; 37: 1577-86.
10. Burger D, Back D. Drug-drug interactions in HIV therapy: is it all clear? Antivir Ther 2013; 18: 649-50.
11. Fungal Pharmacology. http://www.fungalpharmacology.com.
12. IMS Institute for Healthcare Informatics. The Use of Medicines in the United States: Review of 2011. http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf.
13. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2013. Oslo: WHO, 2012.
14. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
15. Andrews J, Guyatt G, Oxman AD et al. GRADEguidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013; 66: 719-25.
16. Balshem H, Helfand M, Schunemann HJ et al. GRADE guidelines: 3 Rating the quality of evidence. J Clin Epidemiol 2011; 64: 401-6.
17. Guimera R, Sales-Pardo M. A network inference method for large-scale unsupervised identification of novel drug-drug interactions. PLoS Comput Biol 2013; 9: e1003374.